The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Drug Eruption Classification

Comprehensive systematic categorization of cutaneous adverse drug reactions (CADRs) according to clinical morphology, severity (mild simple eruption versus severe cutaneous adverse reactions SCARs with significant mortality), pathogenetic mechanism (immunologic — Type I IgE-mediated immediate, Type II cytotoxic, Type III immune complex, Type IV delayed cell-mediated; non-immunologic — toxic, accumulative, idiosyncratic, photoreactive), and timing of onset (immediate < 1 hour, accelerated 1-72 hours, late > 72 hours, delayed weeks to months); essential framework for diagnosis, treatment decisions, and patient counseling about future drug exposures; classification systems include morphologic patterns (exanthematous/maculopapular most common 75-95 percent, urticarial, fixed drug eruption, lichenoid, pustular, bullous, vasculitic, photo-distributed) and severity-based (uncomplicated versus severe — Stevens-Johnson syndrome SJS, toxic epidermal necrolysis TEN, drug reaction with eosinophilia and systemic symptoms DRESS, acute generalized exanthematous pustulosis AGEP, generalized bullous fixed drug eruption GBFDE), with critical recognition of red flags including mucosal involvement, facial edema, fever, lymphadenopathy, eosinophilia, skin pain, blistering, and Nikolsky sign indicating need for urgent specialized management.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Dermatoloji department. Book Appointment →

What is Drug Eruption Classification?

Drug eruption classification is the systematic categorization of cutaneous adverse drug reactions (CADRs) according to multiple parameters including clinical morphology, pathogenetic mechanism, severity, and timing of onset relative to drug exposure. CADRs represent one of the most common adverse drug reactions overall (approximately 30 percent of all ADRs), affecting 2-3 percent of hospitalized patients with most being mild but a small percentage representing life-threatening severe cutaneous adverse reactions (SCARs). Proper classification is essential for diagnosis, treatment selection, prognosis estimation, prevention of recurrence, and patient counseling about future drug exposures and cross-reactivity with related medications.

Morphologic classification: 1) Exanthematous/maculopapular drug eruption — most common form (75-95 percent of all drug eruptions); appears as symmetric erythematous macules and papules typically beginning on trunk and spreading peripherally; usually 4-21 days after drug initiation (1-2 days with re-exposure); common offenders include antibiotics (aminopenicillins, sulfonamides, cephalosporins), antiepileptics (carbamazepine, phenytoin, lamotrigine), allopurinol, NSAIDs, captopril; usually mild and self-limited; 2) Urticarial — affects 10-20 percent of CADRs; characterized by transient pruritic wheals lasting < 24 hours individually but new lesions continually appearing; immediate IgE-mediated (penicillins, NSAIDs) or non-immunologic mast cell degranulation (opiates, contrast media, vancomycin red man syndrome from rapid infusion); 3) Fixed drug eruption (FDE) — well-demarcated solitary or few round/oval erythematous patches that progress to violaceous, often with central duskiness, blistering possible; recur at exactly same site upon re-exposure; pigmentation post-resolution; common offenders sulfonamides, NSAIDs, tetracyclines, barbiturates, paracetamol, antiretrovirals; generalized bullous FDE (GBFDE) is a severe variant resembling SJS/TEN with multiple sites; 4) Lichenoid drug eruption — resembles lichen planus with violaceous flat-topped papules, may have Wickham's striae; common offenders include ACE inhibitors, beta-blockers, gold salts, antimalarials, thiazides, hydroxyurea, anti-TNF agents, immune checkpoint inhibitors; 5) Pustular — acute generalized exanthematous pustulosis AGEP characterized by sudden development of small non-follicular pustules on erythematous edematous background with fever and leukocytosis; common offenders include beta-lactam antibiotics, macrolides, calcium channel blockers, hydroxychloroquine, terbinafine; resolves with desquamation; 6) Bullous — Stevens-Johnson syndrome (SJS, < 10 percent BSA detachment) and toxic epidermal necrolysis (TEN, > 30 percent BSA detachment) with mucosal involvement, fever, prodrome; common offenders sulfonamides, antiepileptics, allopurinol, NSAIDs, nevirapine; high mortality requiring urgent burn unit management; 7) Vasculitic — palpable purpura, urticarial vasculitis, polyarteritis nodosa-like; common offenders propylthiouracil, hydralazine, minocycline, allopurinol; 8) Photo-distributed — sun-exposed areas affected; phototoxic (immediate, dose-dependent — psoralens, tetracyclines, fluoroquinolones, thiazides, voriconazole, vemurafenib) versus photoallergic (delayed, immune-mediated — sulfonamides, NSAIDs, ketoprofen).

Mechanistic classification (Gell and Coombs hypersensitivity types): 1) Type I (immediate IgE-mediated) — minutes to hours; mediated by drug-specific IgE antibodies on mast cells; manifestations include urticaria, angioedema, anaphylaxis; common with penicillins, cephalosporins, NSAIDs (selective for COX-1), contrast media; 2) Type II (cytotoxic) — drug or drug metabolite binds to cell surface, drug-specific IgG or IgM antibodies bind, complement activation and cell destruction; manifestations include drug-induced thrombocytopenia (heparin, quinine, NSAIDs), hemolytic anemia (penicillin, methyldopa, levodopa), neutropenia; 3) Type III (immune complex-mediated) — circulating immune complexes deposit in tissues; manifestations include serum sickness, vasculitis, urticarial vasculitis; 4) Type IV (delayed cell-mediated) — T-cell mediated; multiple subtypes IV-a through IV-d explaining different clinical phenotypes; IV-a (Th1, monocyte-mediated — contact dermatitis), IV-b (Th2, eosinophil-mediated — DRESS, exanthematous), IV-c (cytotoxic CD8+ T cells — SJS/TEN, exanthematous), IV-d (T cells with neutrophilic involvement — AGEP); 5) Non-immunologic mechanisms — toxic effects (phototoxicity), idiosyncratic (drug-induced porphyria, drug-induced lupus), accumulation (pigmentation from minocycline, amiodarone), exacerbation of pre-existing skin disease (NSAIDs and psoriasis, lithium and acne).

Severity-based classification — Severe Cutaneous Adverse Reactions (SCARs): 1) Stevens-Johnson syndrome (SJS) — < 10 percent body surface area (BSA) skin detachment, target lesions, mucosal involvement (oral, ocular, genital), fever, prodrome of upper respiratory symptoms; mortality 5-10 percent; common drugs include sulfonamides, antiepileptics (phenytoin, carbamazepine, lamotrigine, phenobarbital), allopurinol, NSAIDs (oxicam family), nevirapine; 2) Stevens-Johnson syndrome/toxic epidermal necrolysis overlap — 10-30 percent BSA detachment; 3) Toxic epidermal necrolysis (TEN) — > 30 percent BSA skin detachment, full-thickness epidermal necrosis, severe mucosal involvement, fever, multiorgan failure possible; mortality 25-40 percent; same drug culprits as SJS; HLA-B*5801 strongly associated with allopurinol-induced SJS/TEN in Han Chinese; HLA-B*1502 associated with carbamazepine-induced SJS/TEN in Asian populations; 4) Drug reaction with eosinophilia and systemic symptoms (DRESS) — also called drug-induced hypersensitivity syndrome (DIHS); delayed onset (2-8 weeks); morbilliform eruption with facial edema, lymphadenopathy, fever, hepatitis, eosinophilia, atypical lymphocytes; common drugs include allopurinol, anticonvulsants, sulfonamides, dapsone, abacavir; HHV-6 reactivation common; mortality 10 percent; relapse possible; 5) Acute generalized exanthematous pustulosis (AGEP) — acute febrile pustular eruption resolving over days; mortality 1-2 percent; 6) Generalized bullous fixed drug eruption (GBFDE) — multiple bullous lesions resembling SJS/TEN but with characteristic FDE features; mortality 22 percent.

Symptoms

Symmetric maculopapular skin eruption (most common — exanthematous)
Pruritus (variable — mild to severe)
Urticarial wheals (immediate — within hours)
Recurrent erythematous patches at same site (fixed drug eruption)
Pustular eruption with fever (AGEP)
Bullous lesions and skin detachment (SJS/TEN)
Mucosal involvement (oral, ocular, genital — RED FLAG)
Facial edema (DRESS)
Fever (systemic — DRESS, AGEP, SJS/TEN)
Lymphadenopathy (DRESS)
Sun-distributed eruption (photo-toxic/allergic)
Skin pain (DRESS, SJS/TEN — RED FLAG)
Atypical target lesions (SJS/TEN)
Nikolsky sign positive (epidermal sloughing — RED FLAG SJS/TEN)
Recent new medication initiation (4-21 days for exanthematous, 2-8 weeks for DRESS)
Anaphylaxis with angioedema, hypotension (Type I IgE)
Eosinophilia in blood work (DRESS)
Atypical lymphocytes (DRESS)
Hepatitis (DRESS — elevated ALT/AST)
Lichen planus-like eruption (lichenoid drug eruption)
Vasculitis with palpable purpura

Risk Factors

Polypharmacy (multiple medications increasing exposure risk)
HIV infection (10-fold increased risk of severe drug eruptions)
Lupus erythematosus and other autoimmune diseases
Genetic factors (HLA-B*5801 with allopurinol, HLA-B*1502 with carbamazepine in Asian populations, HLA-B*5701 with abacavir)
Slow acetylator phenotype (sulfonamide reactions)
Epstein-Barr virus or HHV-6/7 infection (predisposes DRESS)
Renal failure (delayed drug clearance, allopurinol risk)
Hepatic dysfunction (altered metabolism)
Female sex (slightly higher risk for exanthematous)
Recent viral infection (predisposes to certain drug rashes — amoxicillin in EBV mononucleosis)
Atopic disease history
Previous adverse drug reaction to related medication (cross-reactivity)
Higher drug doses or rapid infusion
Specific drug categories (antibiotics, antiepileptics, allopurinol, NSAIDs, biologics)
Older age (DRESS more common in older patients)
Asian, Black, or Indigenous ancestry (specific HLA risk alleles)
Family history of severe drug reactions
Concomitant herbal supplements interacting with metabolism

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • New skin eruption after starting medication
  • Pruritic rash worsening despite antihistamines
  • Urticaria with breathing difficulty or facial swelling (EMERGENCY)
  • Fever with skin eruption (RED FLAG)
  • Mucosal involvement (mouth, eye, genital lesions — URGENT)
  • Skin blistering or peeling (URGENT — possible SJS/TEN)
  • Skin pain (RED FLAG SJS/TEN)
  • Facial edema with rash (RED FLAG DRESS)
  • Lymphadenopathy with rash
  • Recurrent rash at same body site after re-exposure (FDE)
  • Dramatic worsening of skin condition
  • Difficulty breathing or swallowing with new rash
  • Hypotension with rash (anaphylaxis — EMERGENCY 112)
  • Eosinophilia with rash and systemic symptoms
  • Hepatitis or kidney dysfunction with rash
  • Bullous lesions covering > 5 percent body surface (URGENT)
  • Nikolsky sign positive (skin slips with light pressure — URGENT)
  • Severe pruritus interfering with sleep
  • Suspected drug reaction in elderly or immunocompromised (lower threshold)

Treatment Methods

01
Initial assessment: detailed drug history (all medications including OTC, supplements, herbal — list with start dates and dose changes), timeline correlation (drug initiation, eruption onset, drug discontinuation), morphology assessment (specific pattern recognition), severity grading (BSA involvement, mucosal sites, vital signs), systemic involvement assessment (fever, lymph nodes, hepatosplenomegaly, oral and genital mucosa), photographic documentation, identification of red flags (mucosal involvement, fever, facial edema, blistering, skin pain, Nikolsky sign, eosinophilia), risk stratification, careful examination including conjunctiva and mucous membranes
02
Diagnostic workup: 1) Complete blood count with differential (eosinophilia in DRESS, atypical lymphocytes), comprehensive metabolic panel (liver function — ALT/AST, kidney function, electrolytes), inflammatory markers; 2) Specific tests for severe forms — IgE level (anaphylaxis), tryptase (mast cell activation), complement (immune complex), urinalysis (kidney involvement), HHV-6 PCR (DRESS); 3) Skin biopsy with H&E and direct immunofluorescence (DIF) — particularly helpful for SJS/TEN (full-thickness epidermal necrosis, scant inflammatory infiltrate), DRESS (interface dermatitis with eosinophils), AGEP (subcorneal pustules), vasculitis (leukocytoclastic vasculitis), bullous pemphigoid versus drug-induced bullous (linear IgG and C3 along basement membrane); 4) Patch testing (delayed reactions — 2-7 days post-application, useful for DRESS, AGEP, exanthematous; should not be performed during acute reaction); 5) Drug provocation testing (gold standard but high risk for severe reactions, contraindicated in SJS/TEN/DRESS); 6) Lymphocyte transformation test (LTT) — research setting; 7) HLA testing for specific high-risk drug-allele associations (HLA-B*5701 prior to abacavir initiation in HIV patients, HLA-B*1502 prior to carbamazepine in Asian populations, HLA-B*5801 prior to allopurinol in Han Chinese)
03
Identification and discontinuation of culprit drug: 1) Most important intervention — stop the suspected offending drug; 2) Algorithm for drug culprit identification — Naranjo algorithm, ALDEN (Algorithm for Drug Causality for Epidermal Necrolysis) for SJS/TEN; consider time of drug introduction, all medications including OTC and herbal, drug class, prior reactions; 3) Stop most likely culprit first; 4) Continue essential medications if no culprit suspicion (avoid unnecessary discontinuation); 5) Avoid known cross-reactive medications (sulfa antibiotic and sulfa diuretics — distinct, less cross-reactivity than thought; penicillin and other beta-lactams — variable cross-reactivity assessment needed); 6) If multiple drug culprits possible, may need to discontinue all and reintroduce essential medications one at a time after recovery; 7) Counsel patient to avoid culprit drug and document allergy clearly in medical records
04
Treatment of mild/uncomplicated drug eruptions (exanthematous, mild urticaria, FDE): 1) Discontinue culprit drug; 2) Topical corticosteroids (medium potency — triamcinolone 0.1 percent, betamethasone 0.05 percent) twice daily for symptomatic relief; 3) Antihistamines for pruritus (hydroxyzine 25-50 mg every 6 hours, diphenhydramine, fexofenadine, cetirizine); 4) Cool compresses; 5) Bland emollients; 6) Generally self-limited 1-2 weeks after drug discontinuation; 7) Avoid scratching to prevent secondary infection; 8) Photoprotection in photo-distributed eruptions
05
Treatment of severe cutaneous adverse reactions (SCARs): 1) IMMEDIATE hospitalization — burn unit or ICU for SJS/TEN, dermatology ward or ICU for DRESS; 2) Discontinue all suspected drugs; 3) Supportive care — fluid resuscitation, electrolyte management (similar to burn protocols), pain management, temperature regulation, prevention of infection (sterile environment, regular cultures), nutritional support (high-calorie, high-protein), wound care (non-adherent dressings, biological dressings — Biobrane, amniotic membrane, cadaver allograft), eye care (frequent ophthalmologic evaluation, lubrication, removal of pseudomembranes, amniotic membrane transplantation if needed), oral care (mouthwashes, soft diet), genital care; 4) Specific treatments — IVIG (intravenous immunoglobulin 1 g/kg/day for 3 days for SJS/TEN, controversial efficacy), cyclosporine (3-5 mg/kg/day for SJS/TEN — emerging evidence of mortality benefit), systemic corticosteroids (controversial in SJS/TEN; widely used in DRESS at 0.5-1 mg/kg/day prednisone with slow taper), tumor necrosis factor inhibitors (etanercept for SJS/TEN — emerging evidence), plasmapheresis; 5) DRESS-specific — systemic corticosteroids (prednisone 0.5-1 mg/kg/day with slow taper over 6-12 weeks to prevent relapse), avoid trigger reactivation, monitor HHV-6/CMV/EBV reactivation, monitor for autoimmune sequelae (thyroiditis, diabetes, lupus); 6) AGEP — discontinue drug, supportive care, topical or systemic corticosteroids, usually resolves in 1-2 weeks
06
Specific treatment by mechanism: 1) Type I IgE-mediated (anaphylaxis, urticaria) — epinephrine for anaphylaxis (0.3-0.5 mg IM, repeat as needed), antihistamines (H1 and H2), corticosteroids (methylprednisolone), albuterol, IV fluids, observation 4-6 hours; 2) Drug-induced thrombocytopenia (Type II) — discontinue drug, platelet transfusion if active bleeding, IVIG if HIT (heparin-induced); 3) Vasculitis (Type III) — discontinue drug, NSAIDs for pain, corticosteroids if severe, supportive; 4) Severe Type IV (DRESS, SJS/TEN) — as above with hospitalization
07
Long-term management and prevention: 1) Document drug allergy in medical records prominently; 2) Provide patient with allergy card or medical alert bracelet; 3) Avoid culprit drug lifelong (severe reactions); 4) Cross-reactivity counseling — penicillin and other beta-lactams (modest cross-reactivity 1-3 percent), sulfa antibiotics versus sulfa-containing diuretics/diabetes drugs (lower cross-reactivity than originally thought, individualized assessment), NSAIDs (selective COX-2 inhibitors safer in NSAID-induced urticaria), antiepileptics (cross-reactivity within group — phenytoin, carbamazepine, phenobarbital share cross-reactivity); 5) Pre-treatment HLA testing for high-risk populations (HLA-B*5701 before abacavir, HLA-B*1502 before carbamazepine in Asian populations, HLA-B*5801 before allopurinol in Han Chinese); 6) Drug desensitization protocols for essential medications (penicillin desensitization, aspirin desensitization in NSAID-sensitive asthma, sulfa desensitization in HIV); 7) Patient education on early recognition of recurrent reactions; 8) Long-term sequelae management for SCARs survivors (ocular complications including symblepharon and corneal scarring requiring lifelong ophthalmologic care, oral and genital scarring, chronic skin changes including post-inflammatory hyperpigmentation, anhidrosis, nail changes; psychological impact)
08
Special populations and considerations: 1) Pregnancy — limited safety data for many drugs and treatments, multidisciplinary management; 2) Pediatric — different drug culprits common (antiepileptics, antibiotics), Mycoplasma-induced rash and mucositis (MIRM) versus drug-induced SJS/TEN; 3) Elderly — increased risk due to polypharmacy, reduced renal clearance; 4) HIV/AIDS — significantly increased risk of severe drug reactions (10-fold), especially with sulfonamides, abacavir, nevirapine; 5) Renal failure — adjust drug doses, allopurinol-related SJS/TEN higher risk; 6) Liver disease — altered drug metabolism; 7) Genetic considerations — pharmacogenomic testing for high-risk populations; 8) Multiple drug allergies syndrome — careful evaluation, usually fewer true allergies than reported, drug provocation testing for clarification when essential; 9) Drug rechallenge — generally avoided for severe reactions, may be considered for mild well-characterized reactions with informed consent and close monitoring

Which Department to Visit?

You can visit our Dermatoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Dermatoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Eczema (Atopic Dermatitis)

Dermatoloji

Atopic dermatitis is a chronic skin disease commonly seen especially in children, flaring with genetic predisposition and environmental triggers.

Psoriasis

Dermatoloji

Psoriasis is an autoimmune disease in which skin cells proliferate rapidly when the immune system mistakenly attacks the skin, leading to thick scaly lesions.

Acne

Dermatoloji

Acne is a skin disease resulting from clogging of hair follicles with oil and dead skin cells, commonly seen in adolescence but can occur at any age.

Rosacea

Dermatoloji

Rosacea is a chronic inflammatory facial skin disease characterized by recurrent flushing, persistent erythema, telangiectasia, and inflammatory papules and pustules. Phymatous change and ocular involvement may complicate advanced disease.

Urticaria (Hives)

Dermatoloji

Urticaria is a skin condition with sudden pink-red wheals and intense itching that may follow an acute or chronic course.

Skin Fungal Infections

Dermatoloji

Skin fungal infections are common, contagious skin diseases caused by dermatophytes and yeast fungi colonizing the upper layers of the skin.

Hair Loss (Alopecia)

Dermatoloji

Alopecia is a general term for hair loss that can be genetic, hormonal, autoimmune, or nutritional; early intervention can slow progression.

Vitiligo

Dermatoloji

Vitiligo is an acquired autoimmune disease in which CD8+ T cells destroy melanocytes, producing well-demarcated depigmented patches. Early, sustained treatment can induce repigmentation and prevent progression; psychosocial impact warrants holistic care.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.